Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
dTub
Скачать

Variant allele frequency in patients with SF3B1-mutated MDS

Автор: VJHemOnc – Video Journal of Hematology & HemOnc

Загружено: 2023-12-11

Просмотров: 391

Описание:

Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, presents research investigating the significance of variant allele frequency (VAF) in patients with SF3B1-mutated myelodysplastic neoplasms (MDS). Patients with SF3B1 VAF of lower than 10% exhibited more adverse disease biology and increased co-mutation frequency compared to those with VAF of ≥ 10%, indicating SF3B1 mutations as the primary genomic driver in high VAF cases, while likely sub-clonal in low VAF cases. Despite this distinction, there were no significant differences in leukemia-free survival (LFS) and overall survival (OS) between the two cohorts. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Variant allele frequency in patients with SF3B1-mutated MDS

Поделиться в:

Доступные форматы для скачивания:

Скачать видео mp4

  • Информация по загрузке:

Скачать аудио mp3

Похожие видео

Real-world insights on redefining post-CD19 CAR T-cell surveillance with ctDNA

Real-world insights on redefining post-CD19 CAR T-cell surveillance with ctDNA

TP53-mutated myeloid malignancies: multi-hit vs single-hit disease and transplant implications

TP53-mutated myeloid malignancies: multi-hit vs single-hit disease and transplant implications

Updated follow-up results of the Phase III GAIA/CLL13 trial

Updated follow-up results of the Phase III GAIA/CLL13 trial

An overview of promising therapeutic approaches being explored in newly diagnosed and R/R myeloma

An overview of promising therapeutic approaches being explored in newly diagnosed and R/R myeloma

Decoding DDX41: clinical impact of germline and somatic mutations in high-risk myeloid neoplasms

Decoding DDX41: clinical impact of germline and somatic mutations in high-risk myeloid neoplasms

Wystąpienie Donalda Trumpa

Wystąpienie Donalda Trumpa

LWY POŻARŁY KSIĄŻĘTA! SENSACJA W LIZBONIE! SPORTING - PSG, SKRÓT MECZU

LWY POŻARŁY KSIĄŻĘTA! SENSACJA W LIZBONIE! SPORTING - PSG, SKRÓT MECZU

"30% mieszkańców nie włączy ogrzewania” — oszczędność czy energetyczna bieda?

WERSOW - GIRL BOSS

WERSOW - GIRL BOSS

REAL NA SZÓSTKĘ! DUBLET MBAPPE, ŚWIETNY MECZ VINIEGO! REAL - MONACO, SKRÓT MECZU

REAL NA SZÓSTKĘ! DUBLET MBAPPE, ŚWIETNY MECZ VINIEGO! REAL - MONACO, SKRÓT MECZU

MRD-guided treatment cessation in multiple myeloma

MRD-guided treatment cessation in multiple myeloma

Przemówił po angielsku. Nawrocki w dyskusji w Davos. Jak wypadł?

Przemówił po angielsku. Nawrocki w dyskusji w Davos. Jak wypadł?

Choice of HMA for newly diagnosed TP53-mutant AML: a COMMAND registry study

Choice of HMA for newly diagnosed TP53-mutant AML: a COMMAND registry study

MCL1 copy number gain is a recurrent mark of venetoclax resistance in patients with CLL

MCL1 copy number gain is a recurrent mark of venetoclax resistance in patients with CLL

Genomics defines neoplastic transformation in multiple myeloma precursor conditions

Genomics defines neoplastic transformation in multiple myeloma precursor conditions

Top amyloidosis updates from ASH 2025: the AQUARIUS trial, CAR T-cells, bispecifics & more!

Top amyloidosis updates from ASH 2025: the AQUARIUS trial, CAR T-cells, bispecifics & more!

SIŁOWE PRZEJĘCIE KRS! Reżim Tuska dokonuje zamachu na państwo prawa!

SIŁOWE PRZEJĘCIE KRS! Reżim Tuska dokonuje zamachu na państwo prawa!

Activity of the FcRH5 bispecific antibody cevostamab after prior BCMA therapy in multiple myeloma

Activity of the FcRH5 bispecific antibody cevostamab after prior BCMA therapy in multiple myeloma

HMAs or chemotherapy with venetoclax and gilteritinib for FLT3-mutated AML

HMAs or chemotherapy with venetoclax and gilteritinib for FLT3-mutated AML

ASH 2023: what to look forward to in the MPN space

ASH 2023: what to look forward to in the MPN space

© 2025 dtub. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: infodtube@gmail.com